Summary Plasma and urinary oestrogens were measured in nine breast cancer patients (eight postmenopausal women and one man) before and during treatment with the aromatase inhibitor 4-hydroxyandrostenedione. Urinary oestrogens were measured by using a highly specific GC-MS method. Plasma levels of oestrone, oestradiol and oestrone sulphate were suppressed by 66.6% (± 3.6%), 57.7% (± 5.1%) and 51.8% (± 6.4%) respectively (P<0.005 for all). Twenty-four hour urinary excretion of total oestrogens, oestradiol, oestriol, 2-hydroxyoestrone, 16&x-hydroxyoestrone and the minor metabolites 16p -and 15a-hydroxyoestrone were all suppressed by mean values ranging from 60% to 82%, (oestradiol: P<0.025, otherwise P<0.005). There were no significant changes in the ratios between the different plasma oestrogens. The finding of sustained plasma and urinary oestrogens at 20-40% compared to their control levels indirectly support a hypothesis of alternative oestrogen sources in postmenopausal breast cancer patients on treatment with 4-hydroxyandrostenedione.
Summary Plasma and urinary oestrogens were measured in nine breast cancer patients (eight postmenopausal women and one man) before and during treatment with the aromatase inhibitor 4-hydroxyandrostenedione. Urinary oestrogens were measured by using a highly specific GC-MS method. Plasma levels of oestrone, oestradiol and oestrone sulphate were suppressed by 66.6% (± 3.6%), 57.7% (± 5.1%) and 51.8% (± 6.4%) respectively (P<0.005 for all). Twenty-four hour urinary excretion of total oestrogens, oestradiol, oestriol, 2-hydroxyoestrone, 16&x-hydroxyoestrone and the minor metabolites 16p -and 15a-hydroxyoestrone were all suppressed by mean values ranging from 60% to 82%, (oestradiol: P<0.025, otherwise P<0.005). There were no significant changes in the ratios between the different plasma oestrogens. The finding of sustained plasma and urinary oestrogens at 20-40% compared to their control levels indirectly support a hypothesis of alternative oestrogen sources in postmenopausal breast cancer patients on treatment with 4-hydroxyandrostenedione.
The aim of contemporary endocrine treatment of advanced breast cancer is to reduce oestrogen stimulation to the tumour cell. This could be achieved either by blocking oestrogen action at the receptor level with antioestrogens or by reducing the oestrogen supply to the tumour cell.
The major pathway of oestrogen production in postmenopausal women is peripheral conversion (aromatisation) of circulating androstenedione (A) into oestrone (Oel) (Grodin et al., 1973) . Aromatase inhibition is a successful approach to achieve plasma oestrogen suppression and tumour shrinkage in postmenopausal women suffering from breast cancer. The 'classic' aromatase inhibitor, aminoglutethimide (Orimetene®), has been in clinical use for more than two decades (L0nning & Kvinnsland, 1988) . The toxic side effects caused by this drug has prompted the development of new and more selective aromatase inhibitors (L0nning et al., 1990 ).
4-Hydroxyandrostenedione (Formestanee, Ciba-Geigy) is a second generation aromatase inhibitor (Brodie et al., 1977) , first reported to cause tumour shrinkage in breast cancer patients in 1984 (Coombes et al., 1984) . In contrast to aminoglutethimide, 4-hydroxyandrostenedione seems to act specifically on the aromatase enzyme (Brodie et al., 1981; Dowsett et al., 1989) . The drug causes few side-effects, and results from phase I and II trials including more than 500 patients have revealed an overall response rate of 26% among unselected patients (L0nning, 1992) .
The biochemical action of aromatase inhibitors in vivo is still incompletely understood. Different aromatase inhibitors like aminoglutethimide, 4-hydroxyandrostenedione (Formestane®, Ciba-Geigy) and CGS 16949 (Fadrazole®, Ciba-Geigy) inhibit aromatisation by 82-98% Jones et al., 1992; L0nning et al., 1991; Reed et al., 1990; Santen et al., 1978 ) . Despite this, several investigators have reported sustained plasma oestrogens at about 30-50% of their control values in treated patients (Dowsett et al., 1989; Dowsett et al., 1990; L0nning et al., 1989b; aromatase inhibitors may act on plasma oestrogen by mechanisms other than aromatase inhibition; aminoglutethimide has been shown to stimulate the metabolism of plasma oestrone sulphate (Oe,S) by enhancing the production of 16a-hydroxylated metabolites (16&-hydroxyoestrone and oestriol) (L0nning et al., 1987; L0nning et al., 1989a; L0nning & Skulstad, 1989) .
So far most studies have evaluated the influence of aromatase inhibitors on plasma oestrogens. However, due to the low levels of plasma oestrogens in patients on treatment with aromatase inhibitors, these steroids can be measured with RIA methods only, in which case there is a risk of nonspecific interactions in the assay. About 60-70% of the oestrogen metabolites are excreted in the urine (Fishman et al., 1966; Zumoff et al., 1968) , and the concentration of urinary oestrogen metabolites is about 100 times the concentration of plasma oestrogens. These urinary oestrogen metabolites may therefore be measured by highly specific GC-MS methods (Fotsis & Adlercreutz, 1987) .
To our knowledge neither plasma OeIS nor urinary oestrogen metabolites have previously been reported in patients treated with 4-hydroxyandrostenedione. This study was designed to test whether sustained plasma Oel and Oe2 levels in breast cancer patients treated with 4-hydroxyandrostenedione are accompanied by sustained plasma Oe1S and urinary oestrogen metabolite excretion. By comparing plasma and urinary oestrogen suppression, non specific interactions in the RIA assay or alteration in oestrogen disposition not related to aromatase inhibition might be reflected in conflicting results.
Patients and methods

Patients
Nine patients with advanced breast cancer (one man and eight postmenopausal women) who were to receive 4-hydroxyandrostenedione because of progressive disease were included in this study. All gave their verbal informed consent. The mean age was 72 years (range 62 to 79 years). No patients were smokers, and none of them received any other hormonal treatment or drugs known to influence drug metabolism. The liver enzymes and plasma creatinine were within the normal range in all patients, indicating normal liver and renal function.
All patients had previously been treated with two or more different endocrine regimens (range two to eight, median three regimens). Any previous hormonal therapy was terminated at least 4 weeks before commencing 4-hydroxyandrostenedione. Two patients had received previous treatment with aminoglutethimide, in which case aminoglutethimide was terminated 4 and 8 weeks before commencing on 4-hydroxyandrostenedione.
Treatment schedule and sampling protocol All patients had i.m. injections of 4-hydroxyandrostenedione 250 mg. The injections were given weekly for the first 6 weeks, thereafter at 2-weekly intervals. Blood and urine sampling were performed before commencing on 4-hydroxyandrostenedione and after 36 to 80 days on treatment. The time interval from the last injection of 4-hydroxyandrostenedione to blood and urine collection in the on-treatment test situation ranged from 2 to 13 days with a median of 7 days.
Twenty-four hour urine was collected in dark glass bottles containing ascorbic acid (final concentration > 4 g 1') to prevent the catechol-oestrogens from undergoing oxidation (Gelbke, 1973) . The urine was pooled, one aliquot was obtained for urinary creatinine measurement, and two aliquots of 50 ml were frozen and stored at -20'C until processing.
Heparinised blood samples were obtained on the morning of the urine collection period between 8 a.m. and 9 a.m. after an overnight fast. Plasma was separated by centrifugation and stored at -20°C until processing.
Analytical methods Plasma oestrogens were measured by modification of RIA methods previously described (Dowsett et al., 1987; L0nning et al., 1989a) . The sensitivity limit for Oel, Oe2 and Oe1S was 2.1 pM, 6.3 pM and 25.9 pM respectively, and the Cv within assay were 4.4% 3.9% and 6%.
The analytical method for the determination of the urinary oestrogen profile based on capillary gas chromatographymass spectrometry (GC/MS) in the selected ion monitoring (SIM) mode has been published (Fotsis & Adlercreutz, 1987) . A significant improvement in the accuracy and precision of the method included the addition of deuterated (d5)ethoxime derivatives (Wiihala et al., 1987) of all ketonic oestrogens as internal standards immediately after hydrolysis of the urine extract. In this way stable-isotope dilution mass spectrometry could be used for all ketonic oestrogens. The final determination is carried out using a Hewlett Packard 5995B quadruple instrument equipped with a 0.2 mm x 12.4 m bonded phase BP 1 (equivalent to silicone SE-30) capillary silica column directly connected to ion source. The coefficients of variation for all fractions and other details regarding the reliability of the procedure have been published (Fotsis & Adlercreutz, 1987; Bannwart et al., 1988) . The following oestrogens were determined: Oestron e (Oel), Oestradiol (Oe2), 2-hydroxyoestrone (2-OHOel), 2-hydroxy-oestradiol (2-OHOe2), 2-methoxyoestrone (2-MeOOel), 4-hydroxyoestrone (4-OHOel), oestriol (Oe3), 16a-hydroxyoestrone (16cc-OHOel), l6,-hydroxy-oestrone (16,-OHOel), 15a-hydroxyoestrone (15-OHOel) and 16-keto-oestradiol (16-KetoOe2).
Creatinine in urine and serum was measured by the method of Jaffe. As none of the patients had any significant change in plasma creatinine values during the investigation period, it was found feasible to use the creatinine clearance value as a 'recovery standard' for urine collection. Thus, to correct for any difference in urine losses between the two test situations, the amount of urinary oestrogens excreted was calculated using the ratio between the highest and the actual creatinine clearance for each patient as a correction factor.
Statistical methods Plasma and urinary oestrogen levels before and during treatment were compared using the Wilcoxon Matched Pair Signed Rank Test. All P-values were expressed as two-tailed.
Results
Plasma oestrogens Plasma oestrogen levels before and during treatment are given in Table I (± 5.1 %) and 51.8% (± 6.4%) respectively. previously reported by others (Dowsett et al., 1989; Reed et al., 1990 Figure 1 Individual plasma levels of oestradiol P-Oe2), oestrone (P-Oel) and oestrone sulphate (P-Oe,S) before and during treatment in 9 breast cancer patients (8 postmenopausal women: 0, and 1 man: U) treated with 250 mg 4-hydroxyandrostenedione i.m. fortnightly.
Discussion
Plasma levels of Oel, Oe2 and Oe,S obtained in our patients before treatment were in the same range as previously reported by us and others for postmenopausal breast cancer patients but plasma Oe,S was in the low normal range (Dowsett et al., 1989; Lonning et al., 1989b; Vermeulen et al., 1983) . The amount of different urinary oestrogen metabolites excreted during 24h was in the same range as previously reported in breast cancer patients (Aldercreutz et al., 1991) . (Santen et al., 1982; Santen et al., 1989; Dowsett et al., 1989; Dowsett et al., 1990) McNeill et al., 1992; Santen et al., 1978) . These methods are sensitive enough to detect aromatase inhibition down to 98-99% (Larner et al., 1992) which may have a slow turnover and could be sustained in the tissue for a long time even when their production is inhibited. While this possibility can not be excluded, we found no correlation between plasma oestrogen suppression and the duration of 4-hydroxyandrostenedione treatment among patients investigated in this study. Results by others (Dowsett et al., 1985b) The major metabolic pathways of oestrogens are hydroxylation in the 2-and 16m-position (Bolt, 1979) . Our results revealed no significant change in the ratio of the 16m-hydroxylated (16cx-OHOel and Oe3) or 2-hydroxylated (2-OHOel) metabolites to Oel in the urine. Thus, in contrast to aminoglutethimide (L0nning et al., 1989a; L0nning & Skulstad, 1989 ) 4-hydroxyandrostenedione does not seem to influence the major oestrogen metabolic pathways in vivo.
The metabolite 4-OHOel, like 2-OHOe2, was little suppressed by treatment with 4-hydroxyandrostenedione. The possibility exists that urinary 4-OHOel could arise from aromatisation of 4-hydroxyandrostenedione. However, as the urinary level of 4-OHOel before treatment was below the detection limit of the method, the result should be interpreted with caution. The contribution of 4-OHOel to total urinary oestrogens before and during 4-hydroxyandrostenedione treatment was 1.6% and 3.8% only. Thus, under any circumstance a direct production of 4-OHOe, from 4-hydroxyandrostenedione most probably would not be of a magnitude of biological importance and may not explain our finding of sustained plasma and urinary oestrogens.
The reason why 2-OHOe2 is relatively moderately suppressed remains unclear. At these low levels, the assay may not be completely specific. The urinary concentration of this metabolite was low. While there was a small increase in the plasma Oe2/Oe1 ratio, the ratio of Oe2/Oe1 in urine was slightly reduced. While previous investigations have suggested a possible influence by 4-hydroxyandrostenedione on the 17p-hydroxysteroid dehydrogenase in vitro (Brodie et al., 1982) , our results do not suggest any influence of 4-hydroxyandrostenedione on this enzyme in vivo. Neither is there any obvious reason why 16P-OHOel was particularly effective suppressed (mean suppression of 82%). However, it should be considered that oestrogen metabolic enzymes have been shown to be influenced by several exogenous factors (Conney, 1986 ), and our current knowledge of the regulation of these enzymes is incomplete.
Considering the plasma oestrogens, it may be noted that the plasma Oe1/Oe1S ratio was reduced in 8/9 patients. This contrasts the findings obtained with aminoglutethimide in which case the Oe1/Oe1S ratio was elevated due to enhancement of Oe1S metabolism (L0nning et al., 1989b) . Our findings seem to exclude any enhancement of Oe1S metabolism by 4-hydroxyandrostenedione, but further studies are needed to assess whether treatment with 4-hydroxyandrostenedione causes a reduction in the Oe1/Oe1S ratio. If this should be the case, it may provide information of clinical importance. Current opinion in the literature is that there is no evidence of a direct secretion of plasma Oe1S in postmenopausal women, as circulating Oe1S seems to be accounted for by production from plasma Oel and Oe2 (Longcope et al., 1972; Ruder et al., 1972; Lonning et al., 1989a 
